Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 3/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7167588 | 0.94 | KMT2A (0.43) | HRH3HRH4KDM4E | |
| SCHEMBL5049486 | 0.86 | SRC (0.43) | HRH4KDM4E | |
| SCHEMBL7163046 | 0.85 | DRD3 (0.52) | DRD3HRH3HRH4 | |
| SCHEMBL7139103 | 0.78 | HRH3 (0.46) | DRD3HRH3KDM4EMET | |
| SCHEMBL7167907 | 0.78 | HRH3 (0.53) | DRD3HRH3HRH4KDM4ESIGMAR1 | |
| SCHEMBL15664017 | 0.78 | HRH3 (0.62) | DRD3HRH3HRH4SIGMAR1 | |
| SCHEMBL13980555 | 0.76 | EGFR (0.46) | HRH4KDM4EMET | |
| SCHEMBL4666072 | 0.74 | SRC (0.45) | KDM4EMET | |
| SCHEMBL7162869 | 0.74 | KDR (0.61) | HRH3MET | |
| SCHEMBL7144131 | 0.74 | LTA4H (0.65) | DRD3HRH3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313726-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |